Single-tube quantitative RT-PCR for monitoring of the response to IFN treatment in CML patients

TO THE EDITOR
The Debate round Table in a past issue of Leukemia 1 dealt with methods used in monitoring of residual disease in chronic myeloid leukemia (CML). Techniques employed in monitoring of the response of patients to interferon-␣ (IFN) treatment include above all the classical cytogenetic method, to a lesser extent Southern blot and fluorescent in situ hybridization, and also more recently the very precise and sensitive competitive reverse transcription-polymerase chain reaction (RT-PCR). [1] [2] [3] According to various studies, IFN induces a complete cytogenetic remission in 5-26% of treated patients. 4 In these cases, a competitive RT-PCR quantifying the BCR/ABL transcript is the only method sensitive enough to monitor further dynamics of the disease. However, in the rest of the cases (74-95%), where only weaker or no cytogenetic response was obtained, we consider the use of competitive RT-PCR, in spite of its advantages, too cumbersome and expensive, especially for routine practice.
Therefore, we have developed a single-tube quantitative RT-PCR assay, as simple as a qualitative RT-PCR. It uses an internal endogenous standard -the transcript of the housekeeping gene BCR. Other methods using an endogenous standard usually work with a transcript, whose structure is quite different from that of the target template; this results in quite different amplification efficiencies of both templates and thus, in quite imprecise quantification. By contrast, in our method, the BCR standard and BCR/ABL target template are part of the same structure, with the same binding site for one of the two PCR primers (Figure 1 ). The amplification efficiencies were proved to be of close similarity. Thus, the conditions of competitive PCR were ensured and the precision of the method increased.
The sense primer 5 for both the BCR standard and the BCR/ABL target is located on exon b2 of the BCR major region, the part which is identical for both templates. The antisense primers are situated on exon b4 for the BCR standard (5′CCT CCT TGG GGA TCT TCG 3′) and on a2 of ABL region for the BCR/ABL target. 5 The standard and target templates differ in length by 34 bp for the b3a2 and by 109 bp for the b2a2 transcript (standard is 361 bp, b3a2 transcript 327 bp and b2a2 transcript 252 bp in size). The sense and antisense primers lying on b2 and a2 exons are external primers for twostep RT-PCR for BCR/ABL generally used for qualitative and competitive RT-PCR in our laboratory. 6 The method was performed as follows. Total RNA was extracted from 10 7 cells by a slightly modified method of Chomczynski and Sacchi 7 and reverse-transcribed by AMV reverse transcriptase using random hexamer primers. PCR was performed in a final volume of 25 l with 0. 480; Norwalk, CT, USA), the reaction was started with 3 min at 95°C, 90 s at 58°C and 90 s at 72°C, and then 35 cycles of 40 s at 94°C, 40 s at 57°C and 60 s at 72°C with a final 7 min extension step at 72°C. The primers were synthesized by Genset (Paris, France), all other reagents for RT and PCR were from Promega (Madison, WI, USA). The PCR products were detected and quantified in ethidium bromide stained 2% NA agarose gel (Pharmacia Biotech, Uppsala, Sweden) by using the UVP imager system (GelBase/Gel Blot SW5100W; UVP, Cambridge, UK). The intensity of the BCR/ABL band was corrected for BCR/ABL and BCR template size differences by factors 1,43 (361 bp/327 bp) or 1,10 (361 bp/252 bp) for b2a2 or b3a2 templates, respectively.
The intensity of residual disease was expressed as a ratio of BCR/ABL to BCR band intensities. Tentatively, the ratio (r) can be converted into the percentage of leukemic cells by the formula: % of leukemic cells = 200 r/ (1 + r) because each leukemic cell contributes transcripts of one normal BCR and one BCR/ABL fusion gene, while the normal cells contribute transcripts of two normal BCR genes. However, this relationship is a mere approximation because the transcriptional intensity is presumed to be directly proportional to the amount of BCR/ABL and BCR genes. Still, it is clear that it is the ratio of abnormal and normal gene expression that can characterize disease evolution. On comparing the results with those of competitive RT-PCR, every relative change of BCR/ABL amount was sensitively followed-up by both methods. The increase of BCR/ABL to BCR ratio signals progression of the disease.
The reproducibility of the assay was statistically evaluated and the coefficient of variance was found to be 9% for b2a2 and 7% for b3a2 template. The sensitivity of the assay is the same as that of the classical cytogenetic method. However, it can be used when the cytogenetic method fails, eg in Ph − BCR/ABL + disease. Working with 10 7 cells, the method is more precise and reproducible. As it works with peripheral blood and nondividing cells, it can be used in cases when bone marrow is inaspirable or mitoses unavailable. Also, more frequent and less invasive analyses can be performed. Comparing these two methods we must be aware of their differences. The results from our laboratory indicate that this simple, rapid and precise method together with competitive RT-PCR, which monitors patients in complete cytogenetic remission, can serve as a useful tool for monitoring the IFN treatment efficacy.
Figure 1
Schematic representation of primer positions on the BCR/ABL and the BCR cDNA.
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Institute of Hematology R Kalbácová and Blood Transfusion C Haskovec Praha, Czech Republic may also contribute to the MDR phenotype. The prognostic value of this gene in AML is still not well defined. Cells exposed to calcein acetoxymethyl ester (calcein-AM) become fluorescent following the cleavage of calcein-AM by cellular esterases which produces a fluorescent derivate, calcein. Pgp and MRP actively extrude the calcein-AM. Therefore, calcein-AM uptake (with specific modulators of Pgp and/or MRP) can be used to assess whether MDR1 and/or MRP are functional. 2 We have shown that calcein-AM can be used in fresh leukemic cells to probe specifically both MRP and Pgp activities at the same time and that MRP and Pgp activities, using this functional test, are prognostic factors for achievement of CR.
